Geode Capital Management LLC Grows Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Geode Capital Management LLC increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 0.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,490,101 shares of the biotechnology company's stock after buying an additional 9,914 shares during the quarter. Geode Capital Management LLC owned 2.35% of Blueprint Medicines worth $129,996,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. grew its position in Blueprint Medicines by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock worth $590,905,000 after acquiring an additional 91,450 shares during the last quarter. Wellington Management Group LLP grew its holdings in Blueprint Medicines by 8.0% during the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after acquiring an additional 316,754 shares during the last quarter. State Street Corp increased its position in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock valued at $255,827,000 after acquiring an additional 385,818 shares in the last quarter. William Blair Investment Management LLC grew its stake in shares of Blueprint Medicines by 16.1% during the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock valued at $169,616,000 after purchasing an additional 269,896 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its holdings in shares of Blueprint Medicines by 1.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,183,682 shares of the biotechnology company's stock valued at $103,241,000 after purchasing an additional 17,175 shares in the last quarter.

Remove Ads

Blueprint Medicines Stock Down 0.0 %

BPMC stock traded down $0.01 during midday trading on Monday, reaching $80.83. 39,551 shares of the company's stock traded hands, compared to its average volume of 761,966. Blueprint Medicines Co. has a 52 week low of $73.04 and a 52 week high of $121.90. The company has a market cap of $5.17 billion, a price-to-earnings ratio of -74.84 and a beta of 0.75. The firm's fifty day moving average price is $90.91 and its 200-day moving average price is $93.54. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on BPMC. Needham & Company LLC reissued a "buy" rating and set a $133.00 price objective on shares of Blueprint Medicines in a report on Tuesday, April 8th. HC Wainwright restated a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. JMP Securities reiterated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Jefferies Financial Group started coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a "buy" rating and a $135.00 price target for the company. Finally, Scotiabank initiated coverage on shares of Blueprint Medicines in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $124.95.

Insider Transactions at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now directly owns 69,266 shares in the company, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,358 shares of company stock worth $2,583,187 in the last quarter. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.